COMPANY

Genascence

HQ: Palo Alto, CA source · genascence.com ↗

Keywords: osteoarthritis Osteo Arthritis Knee Knee Osteoarthritis Knee Arthritis Osteoarthritis Knee Arthritis Knee Arthritis Disease Osteo Arthritis of the Knee Osteoarthritic Knee Pain Osteoarthritis (OA) of the Knee Pain (Knee) Gene Therapy GNSC-001 GNSC-001

Location: Palo Alto, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

2027-07 Trial start Phase 2/Phase 3: Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis source ↗
Jun 12, 2023 Trial start Phase 1: Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis source ↗

Upcoming milestones

2029-10 (ESTIMATED) · Phase 2/Phase 3 · Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis · NCT07831577

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07831577	Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis	Phase 2/Phase 3	Not yet recruiting	2027-07	2029-10 (estimated)
NCT05835895	Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis	Phase 1	Active, not recruiting	Jun 12, 2023	Apr 8, 2025 (actual)